These findings provide the first clinical evidence that LAG-3 and TIGIT blockade may help restore T-cell function and offer a novel immunotherapy approach in relapsed MM; however, a longer follow-up is warranted to confirm the durability and impact of these responses. This evidence concerns the gene LAG3 and Miyoshi myopathy.